608
/ 3SBio
- LARVOL DELTA
Home
Next
Prev
1 to 12
Of
12
Go to page
1
December 04, 2025
Phase III Study of 608 in the Treatment of Active Ankylosing Spondylitis in Adults
(clinicaltrials.gov)
- P3 | N=500 | Recruiting | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
New P3 trial • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Rheumatology • Seronegative Spondyloarthropathies
March 11, 2025
A Study to Evaluate 608 in Patients with Non- Radiographic Axial Spondyloarthritis (nr-axSpA)
(clinicaltrials.gov)
- P2 | N=180 | Recruiting | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Seronegative Spondyloarthropathies • Spondylarthritis • CRP
March 11, 2025
A Phase 3 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants with Moderate-to-Severe Plaque Psoriasis
(clinicaltrials.gov)
- P3 | N=458 | Completed | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Recruiting ➔ Completed
Trial completion • Dermatology • Immunology • Psoriasis
October 23, 2024
A Study to Evaluate 608 in Patients with Ankylosing Spondylitis (AS)
(clinicaltrials.gov)
- P2 | N=250 | Active, not recruiting | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Not yet recruiting ➔ Active, not recruiting
Enrollment closed • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Rheumatology • Seronegative Spondyloarthropathies • CRP
March 12, 2024
An Phase III Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With PsO
(clinicaltrials.gov)
- P3 | N=750 | Not yet recruiting | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
New P3 trial • Dermatology • Immunology • Psoriasis
February 16, 2024
A Study to Evaluate 608 in Patients With Ankylosing Spondylitis (AS)
(clinicaltrials.gov)
- P2 | N=250 | Not yet recruiting | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
New P2 trial • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Rheumatology • Seronegative Spondyloarthropathies • CRP
January 25, 2024
A Study to Evaluate 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)
(clinicaltrials.gov)
- P2 | N=180 | Not yet recruiting | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
New P2 trial • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Seronegative Spondyloarthropathies • Spondylarthritis • CRP
January 13, 2023
A Phase 3 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis
(clinicaltrials.gov)
- P3 | N=450 | Recruiting | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Not yet recruiting ➔ Recruiting | Trial primary completion date: Jun 2024 ➔ Jul 2023
Enrollment open • Trial primary completion date • Dermatology • Immunology • Psoriasis
November 08, 2022
A Phase 2 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis
(clinicaltrials.gov)
- P2 | N=139 | Active, not recruiting | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Recruiting ➔ Active, not recruiting
Enrollment closed • Dermatology • Immunology • Psoriasis
November 03, 2022
A Phase 2 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis
(clinicaltrials.gov)
- P2 | N=139 | Recruiting | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
New P2 trial • Dermatology • Immunology • Psoriasis
October 19, 2022
A Phase 3 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis
(clinicaltrials.gov)
- P3 | N=450 | Not yet recruiting | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Trial primary completion date: Sep 2023 ➔ Jun 2024
Trial primary completion date • Dermatology • Immunology • Psoriasis
September 13, 2022
A Phase 3 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis
(clinicaltrials.gov)
- P3 | N=450 | Not yet recruiting | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
New P3 trial • Dermatology • Immunology • Psoriasis
1 to 12
Of
12
Go to page
1